Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis

Hatori, Takashi; Ohsawa, Hidefumi; Uchi, Takashi; Noike, Hirofumi; Kanai, Masahito; Yoshinuma, Masaki; Miyashita, Yoh; Watanabe, Hitoshi; Shirai, Kohji

doi:10.1016/s0021-9150(00)00413-5

Cited by 62 publications

(44 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hitsumoto et al [40,41] compared pre-heparin LPL mass in men with angiographically determined coronary atherosclerosis versus that in men with normal coronary or healthy men. They found that men with coronary atherosclerosis had significantly lower pre-heparin LPL mass than did men without coronary atherosclerosis or healthy men.…”

Section: The Association Of Pre-heparin Lpl Mass and The Incidence Ofmentioning

confidence: 99%

See 1 more Smart Citation

Serum lipoprotein lipase mass: Clinical significance of its measurement

Kobayashi

Nohara

Kawashiri

et al. 2007

Clinica Chimica Acta

View full text Add to dashboard Cite

Section: The Association Of Pre-heparin Lpl Mass and The Incidence Ofmentioning

confidence: 99%

“…They suggest that serum LPL mass is an independent determinant of incidence [40] or severity [41] of coronary artery disease even after adjustments of a number of metabolic parameters, including serum triglycerides and HDL-C.…”

Section: The Association Of Pre-heparin Lpl Mass and The Incidence Ofmentioning

confidence: 99%

Serum lipoprotein lipase mass: Clinical significance of its measurement

Kobayashi

Nohara

Kawashiri

et al. 2007

Clinica Chimica Acta

View full text Add to dashboard Cite

“…Preheparin LPL mass has also been shown to be low in diabetic patients and to be increased by an insulinsensitizing agent 22,23) . Furthermore, preheparin LPL mass has been reported to correlate negatively with the amount of visceral fat and the severity of coronary atherosclerosis 24,25) . Therefore, preheparin LPL mass may be considered to be a quantitative indicator of insulin resistance throughout the whole body 26,27) , and low levels of preheparin LPL mass could be a high risk for atherosclerosis.…”

Section: Discussionmentioning

confidence: 99%

Effect of Combination Therapy of Benidipine Hydrochloride and Candesartan Cilexetil on Serum Lipid Metabolism and Blood Pressure in Elderly Hypertensive Patients with Type 2 Diabetes Mellitus

Sasaki

Kanai

Oyama

et al. 2006

JAT

Self Cite

View full text Add to dashboard Cite

The effects of combination therapy of angiotensin receptor blockers (ARBs) and a calcium antagonist, benidipine hydrochloride, on glucose and lipid metabolism and pulse pressure were studied in elderly hypertensive patients with type 2 diabetes mellitus. Twenty-five hypertensive diabetic patients aged 65 years or older, who had been receiving candesartan cilexetil, were administered benidipine hydrochloride (4 mg/day) and followed for 4 months. After 4 months, systolic and diastolic blood pressure decreased significantly from 154/91 mmHg to 139/78 mmHg (p 0.01 versus before benidipine hydrochloride administration). Body mass index (BMI) and glycosylated hemoglobin (HbA1c) were apparently reduced but the changes were not statistically significant. The serum lipid profile showed no significant changes in serum total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C). Serum lipoprotein lipase mass levels (preheparin LPL mass) increased significantly from 51 to 59 ng/dL (p 0.01 versus before benidipine hydrochloride administration), and the LDL/HDL motility ratio calculated from PAG disc electrophoresis decreased significantly (p 0.05 versus before benidipine hydrochloride administration). When patients were divided into a systolic hypertension group (systolic blood pressure ≥ 140 mmHg and diastolic blood pressure 90 mmHg) and non-systolic hypertension group (others), preheparin LPL mass was significantly lower in the systolic hypertension group, and the decrease in pulse pressure and increase in preheparin LPL mass were significantly greater in the systolic hypertension group. Stepwise regression analysis showed that low preheparin LPL mass at baseline was associated with a decrease in pulse pressure. Add-on benidipine hydrochloride therapy in elderly hypertensive patients with type 2 diabetes mellitus significantly decreases the LDL/HDL motility ratio and pulse pressure, and significantly increases preheparin LPL mass, in addition to improving blood pressure control. These findings suggest that combination therapy with benidipine hydrochloride and candesartan cilexetil may contribute to the suppression of arteriosclerosis and may be useful for elderly hypertensive patients with diabetes mellitus.

show abstract

“…Both t-adiponectin and s-LpL were selected as independent variables for AMI as a subordinate factor. We divided the subjects into three groups based on s-LpL and serum t-adiponectin levels (cut-off levels: s-LpL 40.0 ng/mL; t-adiponectin 4.0 g/mL) 5,6,18,19) and performed multiple logistic regression analysis for AMI as a subordinate factor (Fig. 4).…”

Section: Multivariate Analysismentioning

confidence: 99%

Relationship between Two AMI Risk Factors: Low Serum Lipoprotein Lipase Mass and Hypoadiponectinemia

Hatori

Takahashi

Iizuka

et al. 2011

JAT

Self Cite

View full text Add to dashboard Cite

Aim: Recent clinical studies have reported that low lipoprotein lipase mass in preheparin serum (s-LpL) and hypoadiponectinemia are important risk factors for acute myocardial infarction (AMI). The aim of this study was to elucidate the relationship between low s-LpL and hypoadiponectinemia, both of which are risk factors for AMI. Methods: One hundred and thirty-seven male patients with AMI and fifty-three males with normal coronary arteries (NCA) were enrolled in the study. Coronary risk factors, including s-LpL and serum total adiponectin concentrations (t-adiponectin), were compared. Results: Both s-LpL and t-adiponectin were significantly lower in patients with AMI than in subjects with NCA (s-LpL, NCA: 48.1 11.0 ng/mL, AMI: 38.9 11.1 ng/mL, p 0.01; t-adiponectin, NCA: 7.7 2.9 g/mL, AMI: 6.

show abstract

Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis

Cited by 62 publications

References 21 publications

Serum lipoprotein lipase mass: Clinical significance of its measurement

Serum lipoprotein lipase mass: Clinical significance of its measurement

Effect of Combination Therapy of Benidipine Hydrochloride and Candesartan Cilexetil on Serum Lipid Metabolism and Blood Pressure in Elderly Hypertensive Patients with Type 2 Diabetes Mellitus

Relationship between Two AMI Risk Factors: Low Serum Lipoprotein Lipase Mass and Hypoadiponectinemia

Contact Info

Product

Resources

About